Stability of Drug Additives to Peritoneal Dialysate
Open Access
- 1 October 1995
- journal article
- research article
- Published by SAGE Publications in Peritoneal Dialysis International
- Vol. 15 (4) , 328-335
- https://doi.org/10.1177/089686089501500408
Abstract
Objective: The primary literature was reviewed to determine the stability of drug additives in peritoneal dialysis solutions. Data Sources: A MEDLINE search and retrieval, covering the period 1981 to 1994, was undertaken to identify relevant original literature. Additional references were identified from citations within the original literature. Non-English literature was excluded unless an English abstract was provided. Study Selection: Forty-nine studies were identified. Of these, 24 were directly related to drug stability, 13 were related to the clinical use of the drug additives but included no stability data, and 12 examined other, nonstability aspects of in vitroactivity of antibiotics, additives, or drug adsorption in peritoneal dialysis bags and tubing. Data Extraction: Data included concentrations of drug additives and dialysate solutions, duration and temperatures of storage conditions, types of assay, and whether they were stability-indicating. Results: Stability was defined as the duration of time that the drug concentration remained at 90% or more of the original concentration. Stability was examined under a large variety of conditions. Thirty-one drugs were identified from 20 manuscripts as single-drug additives. Most beta-Iactams were stable for 1 –2 weeks in a refrigerator and for several days at room temperature. Aminoglycosides were stable for 1 –2 days at room temperature. Glycopeptides were stable for several weeks refrigerated or at room temperature. Prolonged storage at room temperature resulted in instability of cefotaxime, ceftazidime, ceftriaxone, and miconazole. Eleven drugs were identified from seven manuscripts as drug combination studies and showed similar stability as single agents. Dialysate concentration appeared to have minimal effect on stability. Conclusions: Drug additives in peritoneal dialysate, singly or combined, should be avoided unless data are available to support their stability. Additives should be made as close as possible to the time of the exchange. Alternatively, additives should be stored refrigerated, then warmed prior to use. The practice of preparing numerous bags at one time should be avoided. Finally, stability data do not indicate sterile integrity of the dialysate.Keywords
This publication has 50 references indexed in Scilit:
- Stability of Ceftazidime and Vancomycin Alone and in Combination in Heparinized and Nonheparinized Peritoneal Dialysis SolutionAnnals of Pharmacotherapy, 1994
- Treatment Recommendations 1993 UpdatePeritoneal Dialysis International, 1993
- Long-term stability of teicoplanin in dialysis fluid: Implications for the home-treatment of CAPD peritonitisInternational Journal of Pharmacy Practice, 1991
- Stability of Ceftriaxone Sodium in Peritoneal Dialysis SolutionsDICP, 1991
- Pharmacokinetics of Calcitriol in Continuous Ambulatory and Cycling Peritoneal Dialysis PatientsAmerican Journal of Kidney Diseases, 1990
- Stability of fosfomycin and qninolones in peritoneal dialysis solutionJournal of Antimicrobial Chemotherapy, 1990
- In vitro bactericidal activities of gentamicin, cefazolin, and imipenem in peritoneal dialysis fluidsAntimicrobial Agents and Chemotherapy, 1989
- Compatibility of Cefazolin and Gentamicin in Peritoneal Dialysis SolutionsDrug Intelligence & Clinical Pharmacy, 1986
- Stability of Single and Combination Antimicrobial Agents in Various Peritoneal Dialysates in the Presence of Insulin and HeparinAmerican Journal of Kidney Diseases, 1983
- Stability of antimicrobial agents in peritoneal dialysateAntimicrobial Agents and Chemotherapy, 1982